Which drug combination for hormone-refractory prostate cancer?
Doggrell, Sheila (2005) Which drug combination for hormone-refractory prostate cancer? Expert Opinion on Pharmacotherapy, 6(4), pp. 667-670.
Impact and interest:
Citation countsare sourced monthly fromand citation databases.
These databases contain citations from different subsets of available publications and different time periods and thus the citation count from each is usually different. Some works are not in either database and no count is displayed. Scopus includes citations from articles published in 1996 onwards, and Web of Science® generally from 1980 onwards.
Citations counts from theindexing service can be viewed at the linked Google Scholar™ search.
|Item Type:||Journal Article|
|Keywords:||Clinical Trial, Docetaxel, Estramustine, Hormone-Refractory Prostate Cancer, Mitoxantrone, Prednisone|
|Subjects:||Australian and New Zealand Standard Research Classification > BIOLOGICAL SCIENCES (060000) > BIOCHEMISTRY AND CELL BIOLOGY (060100)|
Australian and New Zealand Standard Research Classification > BIOLOGICAL SCIENCES (060000) > MICROBIOLOGY (060500)
Australian and New Zealand Standard Research Classification > MEDICAL AND HEALTH SCIENCES (110000) > PHARMACOLOGY AND PHARMACEUTICAL SCIENCES (111500)
|Deposited On:||25 Aug 2011 08:14|
|Last Modified:||29 Feb 2012 23:59|
Repository Staff Only: item control page